IL-21 variants

Details IL-21 variants IL-21 variants

2006-04-18

2011-10-11

Jiang, Dong (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S351000, C435S069520

Reexamination Certificate

active

08034326

ABSTRACT:
IL-21 variant are provided wherein amino acids have been deleted and/or substituted in the region consisting of amino acid No. 65-96.

REFERENCES:
patent: 4902502 (1990-02-01), Nitecki et al.
patent: 5494662 (1996-02-01), Kohji et al.
patent: 5643756 (1997-07-01), Kayman et al.
patent: 6307024 (2001-10-01), Novak et al.
patent: 6423685 (2002-07-01), Drummond et al.
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 6929932 (2005-08-01), Presnell et al.
patent: 7148220 (2006-12-01), Vite et al.
patent: 7186805 (2007-03-01), Presnell et al.
patent: 7250274 (2007-07-01), Chan et al.
patent: 7276478 (2007-10-01), Sivakumar et al.
patent: 7528104 (2009-05-01), Holmes et al.
patent: 2003/0003545 (2003-01-01), Ebner et al.
patent: 2003/0108549 (2003-06-01), Carter et al.
patent: 2003/0186387 (2003-10-01), Ebner et al.
patent: 2004/0009150 (2004-01-01), Nelson et al.
patent: 2004/0228833 (2004-11-01), Costantino et al.
patent: 2006/0024268 (2006-02-01), Kasaian et al.
patent: WO 00/53761 (2000-09-01), None
patent: WO 03/028630 (2003-04-01), None
patent: WO 03/040313 (2003-05-01), None
patent: WO 03/082212 (2003-10-01), None
patent: WO 03/087320 (2003-10-01), None
patent: WO 03/103589 (2003-12-01), None
patent: WO 2004/055168 (2004-07-01), None
patent: WO 2004/112703 (2004-12-01), None
patent: WO 2005/035565 (2005-04-01), None
patent: WO 2005/052139 (2005-06-01), None
patent: WO 2006/111524 (2006-10-01), None
patent: WO 2006/135385 (2006-12-01), None
patent: WO 2008/074863 (2008-06-01), None
Kelso, A., Cytokines: Principles and prospects, Immunology and Cell Biology, vol. 76, pp. 300-317 (1998).
Smyth, M.J. et al., Cytokines in cancer immunity and immunotherapy, Immunological Reviews, vol. 202, pp. 275-293 (2004).
Asao et al., “Cutting Edge: The Common y-Chain is an Indispensable Subunit of the IL-21 Receptor Complex1”, The Journal of Immunology, Jul. 1, 2001, 167(1), 1-5.
Blohm et al., “Lack of Effector Cell Function and Altered Tetramer Binding of Tumor-Infiltrating Lymphocytes”, The Journal of Immunology, Nov. 15, 2002, 169(10), 5522-5530.
Bondensgaard et al., “The Existence of Multiple Conformers of Interleukin-21 Directs Engineering of a Superpotent Analogue”, The Journal of Biological Chemistry, Aug. 10, 2007, 282(32), 23326-23336.
Brandhuber et al., “Three-Dimensional Structure of Interleukin-2”, Science 238, Dec. 18, 1987, 238(4834) 1707-1709.
Brandt et al., “The B7 Family Member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in Humans,” Journal Exp. Med., Jun. 15, 2009, 206(7), 1495-1503.
Brandt, C et al., Journal of Leukocyte Biology Suppl. S 119, Nov. 8-11, 2001, 2 pages.
Collins, et al., “IL-21 and IL-21 Receptor A New Cytokine pathway modulates innate and adaptive immunity”, Immunological Research, 2003, 28(2), 131-140.
Communication from the EP Examining Division dated Jun. 3, 2009, Issued in corresponding EP Application No. 04762905.0, 8 pages.
Delgado et al., “Critical Reviews in Therapeutic Drug Carrier Systems”, 1992, 9(3-4), 249-304.
Dunn et al., “Cancer Immunoediting: From Immunosurveillance to Tumor Escape”, Nature Immunology, Nov. 2002, 3(11), 991-998.
Genmab “Genmab Presents new Humax-CD20 and Humax-EFGr Pre-Clinical Data”, Genmab New Release, Feb. 7, 2003, 1-3.
Hage et al., “Crystal Structure of the Interleukin-4/Receptor a Chain Complex Reveals a Mosaic Binding Interface”, Cell Press, Apr. 16, 1999, 97(2), 271-281.
International Preliminary Report on Patentability issued Jun. 24, 2009 in corresponding International Application No. PCT/EP2007/064326, 6 pages.
Kataki et al., “Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression”, Nov. 2002, 140(5), 320-328.
Katre, “The Conjugation of proteins with polyethylene glycol and other polymers: Altering properties of proteins to enhance their therapeutic potential”, Advanced Drug Delivery Reviews, Jan.-Apr. 1993, 10(1), 91-114.
Khong et al., “Natural Selection of Tumor variants in the generation of “tumor escape” phenotypes”, Nat. Immunol., Nov. 2002, 3(11), 999-1005.
Kinstler et al., “Mono-N-Terminal poly(ethylene glycol)—protein conjugates”, Advanced Drug Delivery Reviews, Jun. 7, 2002, 54(4), 477-485.
Knauf et al., “Relationships of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers”, J. Biol. Chem. Oct. 15, 1988, 263(29), 15064-15070.
Leonard et al., “Interleukin-21: A Modulator of Lymphoid Proliferation , Apoptosis and Differentiation”, Nature Reviews Immunology, Sep. 2005, 5(9), 688-698.
Mehta et al., “Biology of IL-21 and the IL-21 Receptor”, Immunological Reviews, Munksgaard XX, Dec. 2004, 202(1), 84-95.
Mott et al., “The Solution Structure of the F42A Mutant of Human Interleukin 2”, Journal of Molecular Biology, Apr. 14, 1995, 247(5), 979-994.
Olosz et al., “Structural Basis for Binding Multiple Ligands by the Common Cytokine Receptor Y-Chain”, The Journal of Biological Chemistry, Jan. 28, 2002, 277(14), 12047-12052.
Parish-Novak et al., “Interleukin 21 and its receptor are involved in NK Cell expansion and Regulation of lymphocyte function”, Nov. 2, 2000, 408(6808), 57-63.
PCT Application No: PCT/EP2007/064326, Preliminary Report on Patentability, Filing date: Dec. 20, 2007, Mailing Date: Jun. 6, 2009, 6 pages.
Powers et al., “Three-Dimensional Solution Structure of Human Interleukin-4 by Multidimensional Heteronuclear Magnetic Resonance Spectroscopy”, Science, Jun. 19, 1992, 256(5064), 1673-1677.
Response to the Jun. 3, 2009 Communication from the EP Examining Division, EP 04762905.0, dated Jan. 6, 2010, 6 pages.
Sivakumar et al., “Interleukin-21 is a T-Helper cytokine that regulates humoral immunity and cell mediated anti-tumor response”, Immunology Black Well Publishing OxFord GB, Mar. 26, 2004, 112, 117-182.
Stengaard-Pedersen et al. “Inherited Deficiency of Mannan-Binding Lectin-Associated Serine Protease 2”, New England Journal of Medicine, Aug. 7, 2003, 349(6), 554-560.
Tony et al., “Design of Human Interleukin-4 Antagonists inhibiting Interleukin-4-dependent and Interleukin-13-dependent responses in T-cells and B-cells with high efficiency”, European Journal of Biochemistry, Jun. 23, 1994, 225(2), 659-665.
Wang et al., “Structure of the Quaternary Complex of Interleukin-2 with it's A,B, and Yc Receptors”, Science, Nov. 18, 2005, 310(5751), 1159-1163.
Wlodaver,A. et al., “Crystal Structure of Human Recombinant Interleukin-4 at 2.25 A Resolution”, Febs Letters, Aug. 31, 1992, 309(1), 59-64.
Zalipsky “Chemistry of Polyethylene Glycol Conjugates with biologically active molecules”, Advanced Drug Delivery Reviews, Sep. 1995, 16(2-3), 157-182.
Zhang et al., “Functional Epitope of Common Y Chain for Interleukin-4 Binding”, European Journal of Biochemistry, Jan. 2002, 269(5), 1490-1499.
Zhang et al., “Human IL-21 and IL-4 bind to partially overlapping epitopes of Common Y-Chain”, Biochemical and Biophysical Research Communications, Jan. 10, 2003, 300(2), 291-296.
Zhang et al., “Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer”, New England Journal of Medicine, Jan. 16, 2003, 348(3), 203-213.
Doerks et al., “Protein annotation: detective work for function prediction”, Trends in Genetics, Jun. 1998, 14(6), 248-250.
Ngo et al., “Computational complexity, protein structure prediction, and the Levinthal paradox”, The Protein Folding Problems and Tertiary Structure Prediction, 1994, 492-495.
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic era&#

Affiliated with

Also associated with

Rating

IL-21 variants does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-21 variants, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-21 variants will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4259685